High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression
Open Access
- 28 September 2011
- journal article
- research article
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 91
Abstract
High expression of the RNA-binding protein RBM3 has previously been found to be associated with good prognosis in breast cancer, ovarian cancer, malignant melanoma and colorectal cancer. The aim of this study was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer. Immunohistochemical RBM3 expression was examined in a tissue microarray with malignant and benign prostatic specimens from 88 patients treated with radical prostatectomy for localized disease. While rarely expressed in benign prostate gland epithelium, RBM3 was found to be up-regulated in prostate intraepithelial neoplasia and present in various fractions and intensities in invasive prostate cancer. High nuclear RBM3 expression was significantly associated with a prolonged time to biochemical recurrence (BCR) (HR 0.56, 95% CI: 0.34-0.93, p = 0.024) and clinical progression (HR 0.09, 95% CI: 0.01-0.71, p = 0.021). These associations remained significant in multivariate analysis, adjusted for preoperative PSA level in blood, pathological Gleason score and presence or absence of extracapsular extension, seminal vesicle invasion and positive surgical margin (HR 0.41, 95% CI: 0.19-0.89, p = 0.024 for BCR and HR 0.06, 95% CI: 0.01-0.50, p = 0.009 for clinical progression). Our results demonstrate that high nuclear expression of RBM3 in prostate cancer is associated with a prolonged time to disease progression and, thus, a potential biomarker of favourable prognosis. The value of RBM3 for prognostication, treatment stratification and follow-up of prostate cancer patients should be further validated in larger studies.Keywords
This publication has 23 references indexed in Scilit:
- Tumor markers in prostate cancer I: Blood-based markersActa Oncologica, 2011
- Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkersActa Oncologica, 2011
- Radical Prostatectomy versus Watchful Waiting in Early Prostate CancerNew England Journal of Medicine, 2011
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- The RNA-Binding Protein RBM3 Is Required for Cell Proliferation and Protects Against Serum Deprivation-Induced Cell DeathPediatric Research, 2010
- A new generation of proto-oncogenes: Cold-inducible RNA binding proteinsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancerLaboratory Investigation, 2009
- Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastropheOncogene, 2008
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- Increased Transcript Level of RBM3, a Member of the Glycine-Rich RNA-Binding Protein Family, in Human Cells in Response to Cold StressBiochemical and Biophysical Research Communications, 1997